INDIVIDUAL ARTICLE: Impact of Acne Vulgaris and Sarecycline on Social/Emotional Functioning and Daily Activities: PROSES Study

February 2024 | Volume 23 | Issue 2 | SF405634s5 | Copyright © February 2024


Published online January 31, 2024

Emmy Graber MD MBAa, Hilary E. Baldwin MDb, Richard G. Fried MD PhDc, Evan A. Rieder MDd, Adelaide A. Hebert MDe, James Del Rosso DOf, Leon Kircik MDg, Linda Stein Gold MDh, Julie C. Harper MDi, Andrew F. Alexis MDj, Siva Narayanan PhDk, Volker Koscielny MDl, Ismail Kasujee PhDl

aThe Dermatology Institute of Boston and Northeastern University, Boston, MA
bAcne Treatment and Research Center, Brooklyn, NY
cYardley Dermatology Associates, Yardley, PA; dPrivate Practice, New York, NY; eUT Health McGovern Medical School, Houston, TX;
fJDR Dermatology Research/Thomas Dermatology, Las Vegas, NV; gIcahn School of Medicine, Mount Sinai, New York, NY;
hHenry Ford Health System, Bloomfield, MI; iThe Dermatology and Skin Care Center of Birmingham, Birmingham, AL;
jWeill Cornell Medical College, New York, NY; kAvant Health LLC, Bethesda, MD; lAlmirall SA, Barcelona, Spain

DISCLOSURES

Dr. Graber reported receiving royalties from Wolters Kluwer Health and served as a consultant/advisor, research investigator, and/or speaker for Almirall SA, Cutera, Digital Diagnostics, Hovione, Keratin Biosciences, La Roche Posay, Lipidor AB, L’Oreal, Ortho Dermatologics, Sebacia, SolGel, Verrica, and WebMD. Dr. Fried served as a research investigator and/or scientific advisor for AbbVie, BI, BMS, Dermavant, Dermira, EPI, Incyte, Janssen, LEO, Lilly, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi Sun, and UCB. Dr. Hebert reported receiving grants and/or honoraria from Almirall SA, Amryt, Arcutis, Dermavant, GSK, Incyte, Leo, Lilly, Novan, Pfizer, and Sun Pharma; and served as a member of Data and Safety Monitoring Board for GSK, Ortho Dermatologics, and Regeneron-Sanofi. Dr. Del Rosso served as a research investigator, consultant/advisor, and/or speaker for AbbVie, Aclaris, Almirall, Amgen (Celgene), AnaptysBio, Arcutis, Athenex, Bausch (Ortho Dermatologics), Biofrontera, BioPharmX, Biorasi, Blue Creek, Botanix, Brickell, Bristol Myers Squibb, Cara Therapeutics, Cassiopea, Dermata, Dermavant, Encore, EPI Health, Ferndale, Galderma, Genentech, Incyte, Jem Health, LEO Pharma, La Roche-Posay, Lilly (Dermira), MC2, NOVAN, Pfizer, Ralexar, Regeneron, Sanofi-Genzyme, Sente, Solgel, Sonoma (Intraderm), Sun Pharma, UCB, Verrica, and VYNE (Foamix/Menlo). Dr. Kircik served as an investigator, speaker, advisory board member, and/or consultant for Abbott Laboratories, Aclaris, Inc, Allergan, Inc, Almirall, Anacor Pharmaceuticals, Inc, Assos Pharma, Astellas Pharma US, Inc, Asubio Pharma Co, Ltd, Berlex Laboratories (Bayer Healthcare Pharmaceuticals), Biogen-Idec, Inc, Biolife, Biopelle, Boehringer Ingelheim, Breckinridge Pharma, Celgene Corporation, Centocor, Inc, Colbar, CollaGenex, Combinatrix, Connetics Corporation, Coria, Dermik Laboratories, Dermira, Inc, Dow Pharmaceutical Sciences, Inc, Dusa Pharmaceuticals, Inc, Eli Lilly & Co, Embil Pharmaceutical Co, Ltd, EOS, Ferndale Laboratories, Inc, Galderma Laboratories, LP, Genentech, Inc, GlaxoSmithKline, PLC, Health Point Ltd, Idera, Inc, Innocutis Medical, LLC, Innovail, Intendis, Inc, Johnson & Johnson, Laboratory Skin Care, Inc, Leo Pharmaceuticals, Inc, L’Oreal SA, 3M, Maruho Co, Ltd, Medical International Technologies, Medicis Pharmaceutical Corp, Merck & Co, Inc, Merz, Nano Bio Corporation, Novartis Pharmaceutical Corporation, Noven Pharmaceuticals, Inc, Nucryst Pharmaceuticals Corporation, Obagi Medical Products, Inc, Onset, Ortho Dermatologics, OrthoNeutrogena, PediaPharma, Inc, Promius Pharma, LLC, PharmaDerm, Pfizer, Inc, PuraCap, QLT, Inc, Quatrix, Quinnova, Serono (Merck-Serono International SA), SkinMedica, Inc, Stiefel Laboratories, Inc, Sun Pharmaceutical Industries, Ltd, Taro, TolerRx, Inc, Triax, UCB, Inc, Valeant Pharmaceuticals North America LLC, Warner-Chilcott, XenoPort, Inc, and ZAGE. Dr. Stein Gold served as an investigator, advisor and/or speaker for Almirall SA, Galderma, Ortho Derm, and Sun. Dr. Harper reported receiving honoraria for serving as a consultant, speaker, and/or investigator for Almirall, Cassiopeia, Cutera, EPI, Galderma, Journey, L’oreal, Ortho, Sol Gel, Sun, and Vyne and received honoraria for holding stocks in Cutera. Dr. Alexis reported receiving grants and/or royalties from Abbvie, Almirall SA, Amgen, Arcutis, Bristol-Myers-Squibb, Cara, Castle, Dermavant, Galderma, Leo, Novartis, Springer, Wiley-Blackwell, Wolters Kluwer Health, Valeant (Bausch Health), and Vyne; and served as a consultant/advisor and/or speaker for Abbvie, Allergan, Almirall SA, Amgen,  Arcutis,Bausch health, Beiersdorf, BMS, Cara, Castle, Cutera, Dermavant, Eli Lilly, EPI, Galderma, Incyte, Janssen, Leo, L’Oreal, Ortho, Pfizer, Sanofi-Genzyme, Sanofi-Regeneron, Swiss American, Regeneron, UCB, VisualDx, and Vyne. Dr. Narayanan reported receiving consulting honoraria or research funding from Almirall, Biogen, Johnson and Johnson, Sarepta Therapeutics, SeaGen, and Takeda. Dr. Koscielny and Dr. Kasujee are employees of Almirall, SA. No other conflicts were reported.

REFERENCES

  1. Dreno B. What is new in the pathophysiology of acne, an overview. J Eur Acad Dermatol Venereol. 2017;31 Suppl 5:8-12. doi:10.1111/jdv.14374 
  2. Martins AM, Marto JM, Johnson JL, et al. A review of systemic minocycline side effects and topical minocycline as a safer alternative for treating acne and rosacea. Antibiotics (Basel). 2021;10(7)doi:10.3390/antibiotics10070757 
  3. Baldwin H. Oral antibiotic treatment options for acne vulgaris. J Clin Aesthet Dermatol. 2020;13(9):26-32. 
  4. Alanazi MS, Hammad SM, Mohamed AE. Prevalence and psychological impact of Acne vulgaris among female secondary school students in Arar city, Saudi Arabia, in 2018. Electron Physician. 2018;10(8):7224-7229. doi:10.19082/7224 
  5. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2163-96. doi:10.1016/S0140-6736(12)61729-2 
  6. Heng AHS, Chew FT. Systematic review of the epidemiology of acne vulgaris. Sci Rep. 2020;10(1):5754. doi:10.1038/s41598-020-62715-3 
  7. Bhate K, Williams HC. Epidemiology of acne vulgaris. Br J Dermatol. 2013;168(3):474-85. doi:10.1111/bjd.12149 
  8. Goulden V, Stables GI, Cunliffe WJ. Prevalence of facial acne in adults. J Am Acad Dermatol. 1999;41(4):577-80. 
  9. Timms RM. Moderate acne as a potential barrier to social relationships: myth or reality? Psychol Health Med. 2013;18(3):310-20. doi:10.1080/13548506.2012.726363 
  10. Revol O, Milliez N, Gerard D. Psychological impact of acne on 21st-century adolescents: decoding for better care. Br J Dermatol. 2015;172 Suppl 1:52-8. doi:10.1111/bjd.13749 
  11. Skin Disease Briefs: Acne by the numbers. American Academy of Dermatology. Accessed 18 October, 2023. https://assets.ctfassets.net/1ny4yoiyrqia/1hPRvLX6as5tVDTlOnnc0Fab92d8745abcdaadce2080a3b181183e/16- 933-bds-Acne-2.pdf 
  12. Dreno B, Layton A, Bettoli V, et al. Evaluation of the prevalence, risk factors, clinical characteristics, and burden of acne scars among active acne patients in Brazil, France, and the USA. J Am Acad Dermatol. 2017;76:AB132. 
  13. Lindberg M, Isacson D, Bingefors K. Self-reported skin diseases, quality of life and medication use: a nationwide pharmaco-epidemiological survey in Sweden. Acta Derm Venereol. 2014;94(2):188-91. doi:10.2340/00015555-1672 
  14. Thiboutot DM, Dreno B, Abanmi A, et al. Practical management of acne for clinicians: An international consensus from the Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2018;78(2 Suppl 1):S1-S23 e1. doi:10.1016/j.jaad.2017.09.078 
  15. Seite S, Deshayes P, Dreno B, et al. Interest of corrective makeup in the management of patients in dermatology. Clin Cosmet Investig Dermatol. 2012;5:123-8. doi:10.2147/CCID.S33172 
  16. Lafrance M, Carey RS. Understanding the Embodied Experience of Acne. Body Soc. 2018;24:55-87. 
  17. Moradi Tuchayi S, Alexander TM, Nadkarni A, et al. Interventions to increase adherence to acne treatment. Patient Prefer Adherence. 2016;10:2091-2096. doi:10.2147/PPA.S117437 
  18. Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(5):945-73 e33. doi:10.1016/j.jaad.2015.12.037 
  19. Farrah G, Tan E. The use of oral antibiotics in treating acne vulgaris: a new approach. Dermatol Ther. 2016;29(5):377- 384. doi:10.1111/dth.12370 
  20. Nakase K, Nakaminami H, Takenaka Y, et al. Propionibacterium acnes is developing gradual increase in resistance to oral tetracyclines. J Med Microbiol. 2017;66(1):8-12. doi:10.1099/jmm.0.000392 
  21. Bienenfeld A, Nagler AR, Orlow SJ. Oral Antibacterial Therapy for Acne Vulgaris: An Evidence-Based Review. Am J Clin Dermatol. 2017;18(4):469-490. doi:10.1007/s40257-017-0267-z 
  22. Del Rosso JQ, Gallo RL, Thiboutot D, et al. Status report from the scientific panel on antibiotic use in dermatology of the American Acne and Rosacea Society. J Clin Aesthet Dermatol. 2016;9(5):11-17. 
  23. Lee TW, Russell L, Deng M, et al. Association of doxycycline use with the development of gastroenteritis, irritable bowel syndrome and inflammatory bowel disease in Australians deployed abroad. Intern Med J. 2013;43(8):919- 26. doi:10.1111/imj.12179 
  24. van Zuuren EJ, Arents BWM, Miklas M, et al. Identifying and appraising patient-reported outcome measures on treatment satisfaction in acne: a systematic review. Br J Dermatol. 2021;185(1):36-51. doi:10.1111/bjd.19675 
  25. Seysara [package insert]. Almirall S.A. 2018. 
  26. Alexis A, Daniels SR, Johnson N, et al. Development of a new patient-reported outcome measure for facial acne: the Acne Symptom and Impact Scale (ASIS). J Drugs Dermatol. Mar 2014;13(3):333-40. 
  27. Hudgens S, Harper JC, Daniels SR, et al. Validation of a new patient-reported outcome measure for facial acne: The Acne Symptom and Impact Scale (ASIS). J Drugs Dermatol. Jun 2015;14(6):552-9. 
  28. Gupta A, Dhande P. Knowledge, Perceptions and psychosocial impact of acne vulgaris: an Indian scenario. J Clin Diagn Res. 2019;13(3):WC01-WC06. 
  29. Akyazı H. Quality of life in adult patients with acne vulgaris before and after treatment. Dicle Med J Dicle Tip Derg. 2011;38:282-288. 
  30. Hazarika N, Archana M. The psychosocial impact of acne vulgaris. Indian J Dermatol. 2016;61(5):515-20. doi:10.4103/0019-5154.190102 
  31. Ogedegbe EE, Henshaw EB. Severity and impact of acne vulgaris on the quality of life of adolescents in Nigeria. Clin Cosmet Investig Dermatol. 2014;7:329-34. doi:10.2147/CCID.S73302 
  32. Tasoula E, Gregoriou S, Chalikias J, et al. The impact of acne vulgaris on quality of life and psychic health in young adolescents in Greece. Results of a population survey. An Bras Dermatol. 2012;87(6):862-9. doi:10.1590/s0365- 05962012000600007 
  33. Someshwar S, Ahire P, Pawar R, et al. Assessment of the impact of acne vulgaris on the quality of life of pre-adolescents in Navi-Mumbai. New Indian Journal of Pediatrics. 2023;(8) 
  34. Girman CJ, Hartmaier S, Thiboutot D, et al. Evaluating health-related quality of life in patients with facial acne: development of a self-administered questionnaire for clinical trials. Qual Life Res. 1996;5(5):481-90. doi:10.1007/ BF00540020 
  35. Saitta P, Grekin SK. A Four-question Approach to Determining the Impact of Acne Treatment on Quality of Life. J Clin Aesthet Dermatol. 2012;5(3):51-7. 
  36. Parajuli N, Kayastha B. Quality of life in patients with acne: a questionnaire study. Nepal J Dermatol Venereol Leprol. 2018;16:45. 
  37. Tan J, Frey MP, Thiboutot D, et al. Identifying the impacts of acne: A Delphi survey of patients and clinicians. J Cutan Med Surg. 2020;24(3):259-266. doi:10.1177/1203475420907088 
  38. Dunn LK, O'Neill JL, Feldman SR. Acne in adolescents: quality of life, self-esteem, mood, and psychological disorders. Dermatol Online J. 2011;17(1):1. 

AUTHOR CORRESPONDENCE

Emmy Graber MD egraber@dermboston.com
Close Menu